靶向EFHD2抑制干扰素-γ信号并改善非酒精性脂肪性肝炎
本研究在NASH患者和饮食诱导的小鼠模型中探究了免疫细胞特异性分子EFHD2的作用。全局或髓系特异性敲除EFHD2可改善肝脏脂肪变性、减少免疫细胞浸润、抑制脂质过氧化诱导的铁死亡并减轻纤维化,同时阻碍NASH相关肝细胞癌的发展。机制上EFHD2与YWHAZ相互作用促进IFNγR2膜转位介导干扰素-γ信号,靶向EFHD2的订书肽在小鼠中显示出治疗潜力。
要点
- NASH患者和小鼠肝脏巨噬细胞/单核细胞中EFHD2表达显著升高
- 髓系EFHD2敲除可阻止TIM4+驻留Kupffer细胞被浸润单核细胞替代
- 靶向EFHD2的订书α-螺旋肽在小鼠中有效保护NASH病理
核心结论
- EFHD2在NASH中发挥关键的免疫调节和炎症作用,是NASH治疗有前景的可成药靶点。
研究设计与样本
- 在NASH患者和两种饮食诱导的NASH小鼠模型中表征肝脏EFHD2表达。
- 采用单细胞RNA测序和双免疫组化探索NASH肝脏中EFHD2表达模式。
- 评估全局和髓系特异性EFHD2缺失对NASH及NASH相关肝细胞癌的影响。
- 通过化学和遗传学研究评估EFHD2作为治疗靶点的潜力。
主要发现
- NASH患者和小鼠肝脏巨噬细胞/单核细胞中EFHD2表达显著升高。
- 全局或髓系特异性敲除EFHD2改善肝脏脂肪变性、减少免疫细胞浸润、抑制脂质过氧化诱导的铁死亡并减轻纤维化。
- EFHD2缺失阻碍NASH相关肝细胞癌的发展。
- 髓系EFHD2敲除阻止TIM4+驻留Kupffer细胞被浸润单核细胞替代,并逆转NASH中巡逻单核细胞和CD4+/CD8+ T细胞比值的下降。
- 髓系EFHD2与胞质YWHAZ(14-3-3ζ)相互作用,促进IFNγR2转位至质膜,介导干扰素-γ信号。
临床怎么用
- 靶向EFHD2的订书α-螺旋肽在小鼠中有效保护NASH病理,支持EFHD2作为NASH治疗靶点的潜力。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The precise pathomechanisms underlying the development of non-alcoholic steatohepatitis (NASH, also known as metabolic dysfunction-associated steatohepatitis [MASH]) remain incompletely understood. In this study, we investigated the potential role of EF-hand domain family member D2 (EFHD2), a novel molecule specific to immune cells, in the pathogenesis of NASH. METHODS: Hepatic EFHD2 expression was characterized in patients with NASH and two diet-induced NASH mouse models. Single-cell RNA sequencing (scRNA-seq) and double-immunohistochemistry were employed to explore EFHD2 expression patterns in NASH livers. The effects of global and myeloid-specific EFHD2 deletion on NASH and NASH-related hepatocellular carcinoma were assessed. Molecular mechanisms underlying EFHD2 function were investigated, while chemical and genetic investigations were performed to assess its potential as a therapeutic target. RESULTS: EFHD2 expression was significantly elevated in hepatic macrophages/monocytes in both patients with NASH and mice. Deletion of EFHD2, either globally or specifically in myeloid cells, improved hepatic steatosis, reduced immune cell infiltration, inhibited lipid peroxidation-induced ferroptosis, and attenuated fibrosis in NASH. Additionally, it hindered the development of NASH-related hepatocellular carcinoma. Specifically, deletion of myeloid EFHD2 prevented the replacement of TIM4+ resident Kupffer cells by infiltrated monocytes and reversed the decreases in patrolling monocytes and CD4+/CD8+ T cell ratio in NASH. Mechanistically, our investigation revealed that EFHD2 in myeloid cells interacts with cytosolic YWHAZ (14-3-3ζ), facilitating the translocation of IFNγR2 (interferon-γ receptor-2) onto the plasma membrane. This interaction mediates interferon-γ signaling, which triggers immune and inflammatory responses in macrophages during NASH. Finally, a novel stapled α-helical peptide targeting EFHD2 was shown to be effective in protecting against NASH pathology in mice. CONCLUSION: Our study reveals a pivotal immunomodulatory and inflammatory role of EFHD2 in NASH, underscoring EFHD2 as a promising druggable target for NASH treatment. IMPACT AND IMPLICATIONS: Non-alcoholic steatohepatitis (NASH) represents an advanced stage of non-alcoholic fatty liver disease (NAFLD); however, not all patients with NAFLD progress to NASH. A key challenge is identifying the factors that trigger inflammation, which propels the transition from simple fatty liver to NASH. Our research pinpointed EFHD2 as a pivotal driver of NASH, orchestrating the over-activation of interferon-γ signaling within the liver during NASH progression. A stapled peptide designed to target EFHD2 exhibited therapeutic promise in NASH mice. These findings support the potential of EFHD2 as a therapeutic target in NASH.
引用
- Fu JT, Liu J, Wu WB, et al. Targeting EFHD2 inhibits interferon-γ signaling and ameliorates non-alcoholic steatohepatitis. J Hepatol. 2024. PMID: 38670321. doi:10.1016/j.jhep.2024.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。